Lymphoma & Plasma Cell Disorders
Conference Coverage
Combo emerges as bridge to transplant in rel/ref PTCL
LA JOLLA, CALIF. – Researchers plan to expand the duvelisib plus romidepsin arm to better understand the occurrence of transaminitis and assess...
News
FDA grants BI-1206 orphan designation for MCL
BI-1206 is under investigation in a phase 1/2a study.
Conference Coverage
GALLIUM: MRD response correlates with outcomes in follicular lymphoma
SAN DIEGO – MRD response at the end of induction correlates with outcomes in previously untreated follicular lymphoma patients receiving...
Conference Coverage
Applying ECHELON-2 results to clinical practice
LA JOLLA, CALIF. – At the annual T-cell Lymphoma Forum, physicians discussed how the ECHELON-2 trial may affect clinical practice.
Latest News
IPH4102 on fast track for Sézary syndrome
The designation is based on results from a phase 1 trial of 35 patients.
News
Umbralisib gains FDA breakthrough designation for MZL
Umbralisib is a PI3K-delta inhibitor being developed for the treatment of adults with marginal zone lymphoma.
Conference Coverage
Novel bispecific CAR shows promise in B-cell malignancies
SAN DIEGO – This is the first in-human study of a bispecific loop CAR in the United States.
From the Journals
Imaging, radiotherapy clarified in new PMBCL guidelines
The new good practice paper from the British Society for Haematology also addresses fertility preservation.
News
Combo treatment may improve quality of life in CTCL
LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus...
Conference Coverage
Are single agents better than chemo for relapsed/refractory PTCL?
LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.
From the Journals
With RRMM and renal impairment, carfilzomib improves survival
In a subgroup analysis from ENDEAVOR, progression-free survival was more than doubled, compared with bortezomib.